Department of Medicine A, Hematology, Oncology and Pulmonary Medicine, University Hospital Muenster, Muenster, Germany.
Institute of Biostatistics and Clinical Research, Westfaelische Wilhelms-Universitaet Muenster, Muenster, Germany.
Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3.
Follicular lymphoma (FL) is the most frequent indolent lymphoma subtype in adults. Maintenance therapy with rituximab is frequently applied to FL patients with complete or partial response following initial chemoimmunotherapy. However, radioimmunotherapy with Y-ibritumomab-tiuxetan represents a therapeutic alternative.
To compare the clinical and the prognostic impact of both therapies, a study collective of n = 56 patients diagnosed with indolent B-cell lymphoma was retrospectively investigated. The study collective was subdivided into two groups: n = 36 patients treated with rituximab maintenance therapy vs n = 20 patients treated with Y-ibritumomab-tiuxetan.
No prognostic differences for performance status, FLIPI score, gender, or B-symptoms were found for Y-ibritumomab-tiuxetan or rituximab maintenance therapy. Overall survival rates and progression-free survival did not differ between both maintenance therapies.
Our retrospective single-center analysis of two patient groups without major differences in prognostic parameters revealed similar outcome with two different maintenance therapies. Hence, Y-ibritumomab-tiuxetan therapy might offer a valuable alternative treatment option for FL patients with partial response. However, large prospective trials are needed to confirm the reported findings.
滤泡性淋巴瘤（FL）是成人中最常见的惰性淋巴瘤亚型。对于初始化疗免疫治疗后完全或部分缓解的 FL 患者，常采用利妥昔单抗维持治疗。然而，Y-碘替比单抗替曲昔单抗放射性免疫治疗也是一种治疗选择。
为了比较两种治疗方法的临床和预后影响，回顾性研究了 n=56 例诊断为惰性 B 细胞淋巴瘤的患者。研究组分为两组：n=36 例接受利妥昔单抗维持治疗与 n=20 例接受 Y-碘替比单抗替曲昔单抗治疗。
对于 Y-碘替比单抗替曲昔单抗或利妥昔单抗维持治疗，在体能状态、FLIPI 评分、性别或 B 症状方面没有发现预后差异。两种维持治疗的总生存率和无进展生存率没有差异。
我们对两组患者进行了回顾性单中心分析，这些患者在预后参数方面没有明显差异，结果显示两种不同的维持治疗方法具有相似的疗效。因此，对于部分缓解的 FL 患者，Y-碘替比单抗替曲昔单抗治疗可能提供了一种有价值的替代治疗选择。然而，需要进行大型前瞻性试验来证实这些发现。
